Cade Parke, DO
Infectious Disease · Oklahoma City, OKNPI 1598124018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Insmed, Inc. at 24.4% of the total. Reporting peaked in 2023 at $280 and has fallen 55.0% since, to $126 in 2024.
Across 71 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$304
- AbbVie$243
- Boehringer Ingelheim$164
- Merck$117
- Inogen, Inc.$89
- Gilead$69
- plus $259 from 11 others
What the payments were for
- Food & beverage$1,245100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 17 | $304 |
| AbbVie(2 entities) | 12 | $243 |
| Boehringer Ingelheim | 9 | $164 |
| Merck | 8 | $117 |
| Inogen, Inc. | 7 | $89 |
| Gilead | 3 | $69 |
| Amgen | 3 | $54 |
| Circassia Inc. | 2 | $38 |
| Sanofi | 2 | $32 |
| Shionogi Inc | 1 | $20 |
| AstraZeneca | 1 | $19 |
| La Jolla Pharmaceutical Company | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| United Therapeutics Corporation | 1 | $17 |
| Inari Medical, Inc. | 1 | $15 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
How this compares
$1,245 in reported general payments places this provider in the 65th percentile of 51 infectious disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 83 | $69,278 |
| ErtapenemErtapenem Sodium | 40 | $7,546 |
| Cefepime Hcl | 51 | $7,326 |
| Vancomycin Hcl | 22 | $4,302 |
| CeftriaxoneCeftriaxone Sodium | 35 | $3,063 |
| Cefazolin Sodium | 28 | $1,292 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Oklahoma City
- Ahmad AshfaqOklahoma City$22K
- Erin McBrideOklahoma City$6K
- Amaury DiazOklahoma City$5K
- Bushra SiddiqueOklahoma City$3K
- Andrea ScottOklahoma City$3K
- Janki AminOklahoma City$3K
- David ChansolmeOklahoma City$2K
- Miranda McGheeOklahoma City$2K
- John HarkessOklahoma City$1K
- Maria AlkozahOklahoma City$829
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.